Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

Anaplastic lymphoma kinase (ALK) sequencing can identify resistance mechanisms and guide next-line therapy in ALK+ non-small-cell lung cancer (NSCLC), but the clinical significance of other rebiopsy findings remains unclear. We analysed all stage-IV ALK+ NSCLC patients with longitudinally assessable...

Full description

Bibliographic Details
Main Authors: Petros Christopoulos, Steffen Dietz, Martina Kirchner, Anna-Lena Volckmar, Volker Endris, Olaf Neumann, Simon Ogrodnik, Claus-Peter Heussel, Felix J. Herth, Martin Eichhorn, Michael Meister, Jan Budczies, Michael Allgäuer, Jonas Leichsenring, Tomasz Zemojtel, Helge Bischoff, Peter Schirmacher, Michael Thomas, Holger Sültmann, Albrecht Stenzinger
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:Cancers
Subjects:
anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)
tumor protein p53 gene (TP53) mutation
tyrosine kinase inhibitor
progression-free survival
overall survival
Online Access:https://www.mdpi.com/2072-6694/11/1/124

Internet

https://www.mdpi.com/2072-6694/11/1/124

Similar Items